Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

Grifols is anticipating a period of strong ... as well as a new bi-weekly dosing approval for Xembify and pipeline products fibrinogen and trimodulin. The drugmaker has been involved in a series ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Mason Capital denuncia ante el regulador español la "falta de transparencia" de Grifols January 13, 2025 Eli Lilly said on Monday it has sued two medical spas for selling unapproved products ...

Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE® net product s ...

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.